Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial

Journal of Clinical Oncology

Volumn 19, Issue 7, 2001, Pages 1935-1942

  Millot, F ^a   Suciu, S ^a   Philippe, N ^a   Benoit, Y ^a   Mazingue, F ^a   Uyttebroeck, A ^a   Lutz, P ^a   Mechinaud, F ^a   Robert, A ^a   Boutard, P ^a   Marguerite, G ^a   Ferster, A ^a   Plouvier, E ^a   Rialland, X ^a   Behard, C ^a   Plantaz, D ^a   Dresse, M F ^a   Philippet, P ^a   Norton, L ^a   Thyss, A ^a   Dastugue, N ^a   Waterkeyn, C ^a   Vilmer, E ^a   Otten, J ^a   more..

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; INFANT; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SKULL IRRADIATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035300618     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.7.1935     Document Type: Article

References (37)

1. Efficacy of high-dose methotrexate in childhood acute lymphoblastic leukemia: Analysis by contemporary risk classification
2. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy
3. Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: Report from the Japanese Children's Cancer and Leukemia Study Group
4. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM 86 without radiotherapy: Results of Dutch Childhood Leukemia Study Group protocol ALL-7 (1988-1991)
5. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of the multicenter trial ALL-BFM 86
6. The enhanced cytotoxicity of combinations of 1-beta- D arabinofuranosylcytosine and methotrexate
7. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside
8. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult lymphoblastic leukemia and non-Hodgkin lymphoma
9. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid
10. Classification, staging and end results of treatment in childhood non-Hodgkin's lymphoma: Dissimilarities from lymphomas in adults
11. Proposals for the classification of the acute leukemias
12. National Cancer Institute sponsored study of classification on non-Hodgkin's Lymphoma: Summary and description of a working formulation for clinical usage
13. A revised European-American classification of lymphoid neoplasm: A proposal from the international lymphoma study group
14. Monoclonal antibodies marking T lymphocytes in paraffin-embedded tissue
15. Monoclonal antibodies marking B lymphocytes in paraffin-embedded tissue
16. Morphologic, immunologic and cytogenetic (MIC) working classification of acute lymphoblastic leukemia
17. Reporting results of cancer treatment
18. Long term sequelae of cancer treatment on the central nervous system in childhood
19. Association of 1800 cGY cranial irradiation with intellectual function in children with acute lymphoblastic leukemia
20. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study
21. Long term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report
22. High-dose methotrexate improves clinical outcome in children with acute lymphohlastic leukemia: St Jude Total Therapy Study X
23. Treatment of leukemia with larges doses of methotrexate and folinic acid: Clinical-biochemical correlates
24. 2 methotrexate
25. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy - A Children's Cancer Group report
26. Synergistic and antagonistic interactions of methotrexate and 1-beta-D-arabinofuranosylcytosine in hepatoma cells
27. Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside
28. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adults acute lymphoblastic leukemia
29. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, spread out or up front, in combination therapy for children with non-T non-B acute lymphoblastic leukemia
30. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study
31. Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: A Pediatric Oncology Group study
32. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and radiotherapy: Results of the trial ALL-BFM 90
33. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
34. Lymphomatous presentation of childhood lymphoblastic leukemia. A subgroup at high risk of early treatment failure
35. 2 intravenous methotrexate